Becton Dickinson and Co (NYSE:BDX) Shares Sold by Janus Henderson Group PLC
Janus Henderson Group PLC lessened its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 17.6% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 652,483 shares of the medical instruments supplier’s stock after selling 139,733 shares during the quarter. Janus Henderson Group PLC owned approximately 0.24% of Becton Dickinson and worth $164,425,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors also recently bought and sold shares of BDX. Harvest Group Wealth Management LLC purchased a new stake in Becton Dickinson and during the 1st quarter worth about $25,000. Hexavest Inc. purchased a new stake in Becton Dickinson and during the 2nd quarter worth about $28,000. Lipe & Dalton purchased a new stake in Becton Dickinson and during the 2nd quarter worth about $28,000. Pinnacle Financial Partners Inc. purchased a new stake in Becton Dickinson and during the 1st quarter worth about $29,000. Finally, Mcmillion Capital Management Inc. purchased a new stake in Becton Dickinson and during the 2nd quarter worth about $40,000. Hedge funds and other institutional investors own 85.07% of the company’s stock.
BDX opened at $244.71 on Thursday. The company has a quick ratio of 0.67, a current ratio of 1.09 and a debt-to-equity ratio of 0.84. The stock has a market cap of $67.26 billion, a PE ratio of 22.23, a price-to-earnings-growth ratio of 1.81 and a beta of 1.11. The company has a 50-day simple moving average of $251.98. Becton Dickinson and Co has a 12 month low of $208.62 and a 12 month high of $265.87.
The firm also recently declared a quarterly dividend, which will be paid on Monday, September 30th. Shareholders of record on Monday, September 9th will be issued a $0.77 dividend. This represents a $3.08 annualized dividend and a yield of 1.26%. The ex-dividend date is Friday, September 6th. Becton Dickinson and’s dividend payout ratio (DPR) is 27.97%.
In other news, EVP Simon D. Campion sold 2,903 shares of the business’s stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $236.94, for a total transaction of $687,836.82. Following the completion of the sale, the executive vice president now owns 9,408 shares in the company, valued at approximately $2,229,131.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Samrat S. Khichi sold 16,085 shares of the business’s stock in a transaction dated Tuesday, May 21st. The stock was sold at an average price of $234.68, for a total value of $3,774,827.80. Following the sale, the executive vice president now owns 12,608 shares of the company’s stock, valued at approximately $2,958,845.44. The disclosure for this sale can be found here. Insiders sold a total of 24,529 shares of company stock valued at $5,836,116 in the last 90 days. 0.12% of the stock is owned by company insiders.
A number of research firms recently commented on BDX. BMO Capital Markets dropped their price objective on Becton Dickinson and from $272.00 to $270.00 and set a “market perform” rating for the company in a research report on Friday, May 10th. Zacks Investment Research upgraded Becton Dickinson and from a “sell” rating to a “hold” rating in a research report on Monday, May 20th. Morgan Stanley lifted their price objective on Becton Dickinson and from $250.00 to $261.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 16th. KeyCorp restated an “overweight” rating and issued a $262.00 price target (down previously from $273.00) on shares of Becton Dickinson and in a report on Friday, May 10th. Finally, Wells Fargo & Co lowered their price target on Becton Dickinson and from $280.00 to $265.00 and set an “outperform” rating for the company in a report on Monday, May 13th. Five analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $264.27.
About Becton Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Further Reading: Investing in Growth Stocks
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.